Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours - Concepedia

Concepedia

Publication | Open Access

Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

DOI Full Paper Access

144

Citations

27

References

2021

Year

Jordi Rodón, Guillem Argilés, Roisín M. Connolly, Ulka N. Vaishampayan, Maja J.A. de Jonge, Elena Garralda, Marios Giannakis, David C. Smith, Jason R. Dobson, Margaret E. McLaughlin,

British Journal of Cancer

Tumor BiologySingle-agent Wnt974OncologyMedicinePathologyAdvanced Solid TumoursPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyPhase 1Novel TherapyCancer ResearchDrug Discovery

References

	Year	Citations

Page 1

Page 1